ArticleCancer gene therapy2009
Nanoparticle delivery of anti-metastatic NM23-H1 gene improves chemotherapy in a mouse tumor model.
Article in Cancer gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Bone Targeting Nanoparticles for the Treatment of Osteoporosis.International journal of nanomedicine · 2024Review
- Development of Positively Charged Poly-L-Lysine Magnetic Nanoparticles as Potential MRI Contrast Agent.Nanomaterials (Basel, Switzerland) · 2023Article
- Nm23-H1 induces apoptosis in primary effusion lymphoma cells via inhibition of NF-κB signaling through interaction with oncogenic latent protein vFLIP K13 of Kaposi's sarcoma-associated herpes virus.Cellular oncology (Dordrecht, Netherlands) · 2022Article
- Review
- Comprehensive analysis of theTranslational cancer research · 2020Article
- Foot-and-mouth disease virus induces lysosomal degradation of NME1 to impair p53-regulated interferon-inducible antiviral genes expression.Cell death & disease · 2018Article
- Nanoparticle-based targeted gene therapy for lung cancer.American journal of cancer research · 2016Article
- Progress on Nme (NDP kinase/Nm23/Awd) gene family-related functions derived from animal model systems: studies on development, cardiovascular disease, and cancer metastasis exemplified.Naunyn-Schmiedeberg's archives of pharmacology · 2015Article
- Mesoporous magnetic gold "nanoclusters" as theranostic carrier for chemo-photothermal co-therapy of breast cancer.Theranostics · 2014Article
- Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene.Cancer metastasis reviews · 2012Review
- Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Review
- Treating metastatic cancer with nanotechnology.Nature reviews. Cancer · 2011Review
- Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-progress and prospects.Advanced drug delivery reviews · 2011Review
- Metastasis-suppressor genes in clinical practice: lost in translation?Nature reviews. Clinical oncology · 2011Review
- Click assembly of magnetic nanovectors for gene delivery.Biomaterials · 2011Article
- Application of magnetic nanoparticles to gene delivery.International journal of molecular sciences · 2011Review
- Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention.Cancer biology & therapy · 2010Review
- Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications.Expert opinion on drug delivery · 2010Review
- The Nm23-H1 metastasis suppressor as a translational target.European journal of cancer (Oxford, England : 1990) · 2010Review
- Immunohistochemical analysis of oxidative stress and DNA repair proteins in normal mammary and breast cancer tissues.BMC cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy provides a promising approach for cancer treatment. Earlier studies suggested that poly-L-lysine-modified iron oxide nanoparticles (IONP-PLL) might be a promising gene delivery system that can transfect DNA efficiently in vitro and in vivo. In this study we used IONP-PLL as gene carriers to deliver the NM23-H1 gene, the first suppressor gene of cancer metastasis, to tumor cells in vivo. The intravenous injection of IONP-PLL carrying NM23-H1-GFP plasmid DNA significantly extended the survival time of an experimental pulmonary metastasis mouse model. In the IONP-PLL/NM23-H1-GFP-treated group, metastasis was clearly suppressed compared with the group treated with free NM23-H1-GFP plasmid. Furthermore, this gene therapy combined with cyclophosphamide treatment resulted in longer survival times and greater suppression of metastasis growth. In conclusion, treatment with IONP-PLL nanoparticles incorporating the NM23-H1gene is an efficient gene therapy method, and it is even more effective in combination with chemotherapy. This approach appears to be a promising strategy for treatment of metastatic tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.